Pricing Debate
Weight loss drugs have likely proven to be the most challenging medicines to introduce to the National Health Service in England, and lessons should be learned in preparation for other game changing products.
Canada’s Drug Agency is also looking to consider the impact on productivity outcomes for both patients and informal caregivers when assessing the value of a drug.
According to the health technology assessment institute, NICE, new cost-effectiveness thresholds – which are higher than those that applied when the original decisions were made – will apply when its committee reconsiders the appraisals for Eisai and Eli Lilly’s Alzheimer’s disease drugs.
A US lawmaker described program reform goals as returning the program to its original focus on supporting federally qualified health centers and rural hospitals.
A new survey of French healthcare professionals reveals concerns that France is increasingly being excluded from major international clinical studies.
Japan's regulatory authorities recommend approval of products including a cell therapy, while setting reimbursement prices of newly approved drugs and cutting some others following cost-effectiveness assessment.
Although the legislation has little chance of passing, it offers some clues about the administration's goals for MFN agreements, which differ from the voluntary deals struck with large pharma companies.
The expansion of the US Medicare drug price negotiation to include Part B products for the first time should be a very big deal, but the impact is not going to be significant in the first year and maybe future years.
Norway’s pharmaceutical industry association says it is waiting to hear from the ministry of health about how it will address the country’s low willingness to pay for innovation.
The program could increase the momentum for establishing a new model for employer-sponsored insurance coverage.
European pricing and reimbursement processes, including in the UK, are on hold for now.
The agency may be prepared to discuss broader voluntary Most Favored Nation agreements with small and mid-size firms during April meetings about the GENEROUS model.
At BIO’s Investor and Growth Summit, panelists said Most Favored Nation pricing in the US is forcing biopharma companies to scrap plans to to out-license ex-US rights to their drugs, a previously common practice.
The CMS proposal to assign liability to manufacturers despite licensing arrangements reflects the agency’s concern that companies will try to game the models.
Trump touted his "big achievement" on drug pricing during his State of the Union address and did not imply other reforms are coming.
The move is aligned with a growing industry shift toward lowering list prices to current net pricing levels and eliminating rebates.
AAM President and CEO John Murphy summarized a year of industry progress in front of generics and biosimilars industry delegates at AAM’s Access! 2026 conference, but also said more efforts were needed to create a sustainable future environment.
Centers for Medicare and Medicaid Services Administrator Mehmet Oz and Pfizer CEO Albert Bourla proposed ways pharma and the Administration could build on the relationships forged through Most Favored Nation pricing deals.
The first round of price caps imposed via Medicare negotiation have taken effect, but if the leading target is any indication, industry appears able to handle the consequences.
Immedica’s Loargys is set to become the first disease modifying treatment for arginase 1 deficiency to be reimbursed in England. Meanwhile, the US regulator is reviewing a resubmitted marketing application for the product and has set a target action date of Feb. 23.